Chapter 1 Introduction
1.1 Executive Summary
1.2 Market Definition
1.3 Scope of the Study
Chapter 2 Research Methodology
2.1 Secondary Research
2.2 Primary Research
2.3 Analytic Tools and Model
2.4 Economic Indicator
2.4.1 Base Year, Base Currency, Forecasting Period
2.5 Expert Validation
2.6 Study Timeline
Chapter 3 Market Analysis
3.1 Industry Value Chain Analysis
3.2 Porter's Five Analysis
3.2.1 Bargaining Power of Buyers
3.2.2 Bargaining Power of Suppliers
3.2.3 Threats of Substitutes
3.2.4 Threats of New Entrants
3.2.5 Industry Rivalry
3.3 PESTLE Analysis
3.3.1 Political
3.3.2 Economical
3.3.3 Social
3.3.4 Technological
3.3.5 Legal
3.3.6 Environmental
3.4 SWOT Analysis
3.4.1 Strengths
3.4.2 Weakness
3.4.3 Opportunities
3.4.4 Threat
3.5 Y-O-Y Analyses
Chapter 4 Market Dynamics
4.1 Drivers
4.2 Restraints
4.3 Opportunities
4.4 Challenges
Chapter 5 Market Segmentation Analysis
Chapter 6 Market Segmentation, By Type
6.1 Monoclonal Antibodies
6.1.1 Anti-Inflammatory Monoclonal Antibodies
6.1.2 Anti-Cancer Monoclonal Antibodies
6.1.3 Other Monoclonal Antibodies
6.2 Recombinant Growth Factors
6.2.1 Granulocyte Colony Stimulating Factor
6.2.2 Erythropoietin
6.3 Purified Proteins
6.3.1 P53 Protein
6.3.2 P38 Protein
6.3.3 Leukemia Inhibitory Factor (LIF)
6.4 Recombinant Proteins
6.4.1 Cathepsin
6.4.2 Caspase
6.4.3 Cyclase
6.4.4 Defensin
6.4.6 Amyloid Protein
6.4.7 Serum Albumin
6.5 Recombinant Hormones
6.5.1 Recombinant Insulin
6.5.2 Recombinant Human Growth Hormone (HGH)
6.6 Synthetic Immunomodulators
6.6.1 Tumor Necrosis Factor (TNF)
6.6.2 Cytokines, Interferons, Interleukins
6.7 Vaccines
6.7.1 Recombinant Vaccines
6.7.1.1 Cholera Vaccine
6.7.1.2 Diphtheria Vaccine
6.7.1.3 Tetanus vaccine
6.7.1.4 Hepatitis-B Vaccine
6.7.1.5 Ebola Vaccine
6.7.1.6 Malaria Vaccine
6.7.1.7 Cancer Vaccines
6.7.2 Conventional Vaccines
6.7.2.1 Pox Vaccine
6.7.2.2 Polio Vaccine
6.8 Recombinant Enzymes
6.8.1 Transferrin
6.8.2 Enterokinase
6.9 Others
Chapter 7 Market Segmentation, By Therapeutic Applications
7.1 Neurological Diseases
7.2 Cardiovascular Diseases
7.3 Disease Prevention
7.4 Hormonal Disorders
7.5 Metabolic Disorders
7.6 Autoimmune Disorders
7.7 Inflammatory and Infectious Diseases
7.8 Oncology
7.9 Other Diseases
Chapter 8 Market Segmentation, By Geography
8.1 North America
8.1.1 Introduction
8.1.2 United States
8.1.3 Canada
8.1.4 Mexico
8.1.5 Others
8.2 Europe
8.2.1 Introduction
8.2.2 U.K
8.2.3 Spain
8.2.4 Italy
8.2.5 France
8.2.6 Russia
8.2.7 Others
8.3 Asia-Pacific
8.3.1 Introduction
8.3.2 China
8.3.3 India
8.3.4 Japan
8.3.5 Australia & New Zealand
8.3.6 Others
8.4 South America
8.4.1 Introduction
8.4.2 Brazil
8.4.3 Argentina
8.4.4 Others
8.5 The Middle East & Africa
8.5.1 Introduction
8.5.2 South Africa
8.5.3 Others
Chapter 9 Competitive Landscape
9.1 Mergers & Acquisitions, Joint Ventures, Collaborations, and Agreements
9.2 Market Share Analysis
9.3 Strategies Adopted By Top Companies
Chapter 10 Company Profiles (Overview, Financials, SWOT Analysis, Developments, Product Portfolio)
10.1. Takeda
10.1.1. Company Overview
10.1.2. Financial Performance
10.1.3. Product Benchmarking
10.1.4. Strategic Initiative
10.2. Sanofi Aventis
10.3. Roche
10.4. Regeneron
10.5. Pfizer
10.6. Novo Nordisk
10.7. Novartis
10.8. Merck & Co
10.9. Johnson & Johnson
10.10. Genentech
10.11. Bristol Myers Squibb
10.12. Biogen
10.13. Bayer
10.14. Amgen
10.15. AbbVie
Chapter 11 Market Estimates and Forecast
11.1 Market Estimates and Forecast 2018-2024(USD Million)
11.1.1 Market Estimation and Forecast by Type 2018-2024 (USD Million)
11.1.1 Market Estimation and Forecast by Therapeutic Applications 2018-2024 (USD Million)
11.1.2 Market Estimates and Forecast by Geography 2018-2024 (USD Million)
Chapter 12 Market Insights
12.1 Insights of Industry Experts
12.2 Analyst Opinion (Market Understanding)
12.3 Investment Opportunities
Chapter 13 Appendix
13.1 List of Tables
13.2 List of Figures
